Premium
DYNAMO: a PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE‐REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA
Author(s) -
Zinzani P.,
WagnerJohnston N.,
Miller C.,
Ardeshna K.,
Tertreault S.,
Assouline S.,
Mayer J.,
Passamonti F.,
Lunin S.,
Pettitt A.,
Nagy Z.,
Tournilhac O.,
AbouNassar K.,
Crump M.,
Jacobsen E.,
De Vos S.,
Youssoufian H.,
Porter J.,
Prado S.,
Flinn I.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_57
Subject(s) - medicine , adverse effect , refractory (planetary science) , gastroenterology , clinical endpoint , regimen , lymphoma , surgery , oncology , clinical trial , physics , astrobiology